Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03159936 · ClinicalTrials.gov registry record · Early Phase 1
Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)
A Early Phase 1 study, sponsored by Tufts Medical Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT03159936: Clinical Trial Early Phase 1 study, sponsored by Tufts Medical Center.
NCT03159936 is a Early Phase 1 study that was terminated before completion, run by Tufts Medical Center. The registered enrollment target is 5 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03159936, a Early Phase 1 study, was terminated before completion, sponsored by Tufts Medical Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
Evaluate the activity and safety of oral tofacitinib in adult patients with discoid lupus erythematosus with or without concurrent SLE.
Primary Outcome
Percent change
Interventions
- BIOLOGICAL Tofacitinib citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-04-03 |
| Est. Completion | 2020-06-10 |
| Phase | Early Phase 1 |
Why NCT03159936 stopped before completion
NCT03159936 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 1 intervention - of which Tofacitinib citrate is the first listed.
NCT03159936 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03159936 about?
NCT03159936 is a clinical study titled "Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)". Evaluate the activity and safety of oral tofacitinib in adult patients with discoid lupus erythematosus with or without concurrent SLE.
What is the current status of trial NCT03159936?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2017-04-03. Estimated completion is 2020-06-10.
What interventions are being tested in trial NCT03159936?
The interventions under investigation include: Tofacitinib citrate (BIOLOGICAL).
Who is sponsoring clinical trial NCT03159936?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03159936's enrollment target sits among peer trials
5 1887th of 2000 higher than 80 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI